Skip to content

Advertisement

  • Poster presentation
  • Open Access

Efficacy of oral versus subcutaneous methotrexate in children with juvenile idiopathic arthritis

  • 1,
  • 1,
  • 2,
  • 3,
  • 4 and
  • 1
Pediatric Rheumatology20086 (Suppl 1) :P79

https://doi.org/10.1186/1546-0096-6-S1-P79

  • Published:

Keywords

  • Rheumatoid Arthritis
  • Methotrexate
  • Visual Analogue Scale
  • Juvenile Idiopathic Arthritis
  • Activity Score

Background

Therapy of juvenile idiopathic arthritis (JIA) is based on, among various other treatments, methotrexate (MTX). Pharmacokinetic data indicate a lower drug resorption rate when applied orally (po) versus subcutaneous (sc) administration.

Objectives

We aimed to compare the effects of po and sc applied MTX on the JIA-disease course.

Methods

According to MTX-administration route, children were divided into four groups: sc, po, switching from po to sc and from sc to po. Based on joint counts (pain, swelling and limited range of motion), patient's and physician's visual analogue scale for disease activity (VAS) and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), a combined overall disease activity score (entitled Co-score, CoS) was generated for each patient. Statistically paired T-test and ANCOVA were applied.

Results

For the sc group, the ESR-CoS improved on average by 2.24 units (CI: 1.57–2.91; p < 0.0001) and the CRP-CoS by 1.61 units (CI: 0.87–2.35; p < 0.0002). In the po group, the ESR-CoS improved by 2.37 units (CI: 1.7–3.04; p < 0.0001) and the CRP-CoS by 2.16 units (CI: 1.48–2.85; p < 0.0001). In the po to sc switcher group, both scores showed insignificant improvement during the po phase (p > 0.05). After the change to sc administration, both scores significantly improved (p < 0.0007 and p < 0.0005 respectively). In the sc to po group, data from only four patients were analyzable and therefore, statistically irrelevant.

Conclusion

Considering data from adult rheumatoid arthritis studies and MTX pharmacokinetics, our results support to some extent sc MTX-administration in children, at least at treatment initiation, emphasizing the need of prospective investigations.

Authors’ Affiliations

(1)
University Children's Hospital, Pediatric Rheumatology, Tuebingen, Germany
(2)
University of Tuebingen, Medical Biometry, Tuebingen, Germany
(3)
University Medical Clinic, Interdisciplinary Rheumatology-INDIRA, Tuebingen, Germany
(4)
Medical Scientific Autoimmune, medac GmbH, Wedel, Germany

References

  1. Balis FM: J Clin Oncol. 1988, 6 (12): 1882-6.PubMedGoogle Scholar
  2. Braun J: Arthritis Rheum. 2008, 58 (1): 73-81. 10.1002/art.23144.View ArticlePubMedGoogle Scholar

Copyright

© Tzaribachev et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement